June Kunapareddy
Dermatology · Terre Haute, INNPI 1124414388
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,200 of the $11,130 with a category attached, or 64.7%. Sun Pharmaceutical Industries Inc. accounts for 79.1% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $9,475, more than ten times the $125 reported in 2019.
Across 93 payments — averaging $119.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$9K
- Johnson & Johnson$742
- Galderma Laboratories, L.p.$280
- Regeneron Healthcare Solutions, Inc.$217
- AbbVie$176
- Sanofi$143
- plus $768 from 11 others
What the payments were for
- Consulting fees$7,20065%
- Travel & lodging$1,23511%
- Food & beverage$2,23220%
- Education$4634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 9 | $8,804 |
| Johnson & Johnson | 33 | $742 |
| Galderma Laboratories, L.p. | 6 | $280 |
| Regeneron Healthcare Solutions, Inc. | 6 | $217 |
| AbbVie | 5 | $176 |
| Sanofi | 4 | $143 |
| Lilly USA, LLC | 7 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| UCB, Inc. | 4 | $86 |
| LEO Pharma Inc. | 4 | $82 |
| Amgen | 3 | $56 |
| Novartis | 2 | $31 |
| Incyte Corporation | 1 | $27 |
| Pfizer | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,130 in reported general payments places this provider in the 80th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 55 | $1,117,258 |
| Cosentyx Unoready PenSecukinumab | 72 | $700,872 |
| Humira(Cf) PenAdalimumab | 24 | $377,400 |
| StelaraUstekinumab | 14 | $200,729 |
| Dupixent PenDupilumab | 55 | $200,174 |
| Taltz AutoinjectorIxekizumab | 24 | $176,058 |
| OtezlaApremilast | 12 | $57,831 |
| Tacrolimus | 122 | $20,509 |
| Fluorouracil | 115 | $9,530 |
| Clobetasol Propionate | 134 | $6,081 |
| Ketoconazole | 190 | $3,842 |
| Metronidazole | 37 | $2,272 |
| Mycophenolate Mofetil | 25 | $2,267 |
| Tazarotene | 14 | $1,937 |
| Clindamycin Phosphate | 44 | $1,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $742 | $200,72914 claims |
| AmgenOtezla | $56 | $57,83112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 dermatology providers in Indiana.
Other dermatology in Terre Haute
- Ryan PattersonTerre Haute$16K
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
- Jeffrey SassmannshausenFort Wayne$489K
- Nikolajs PerdueIndianapolis$302K
- Michael SheehanColumbus$297K
- Alfred KnableNew Albany$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.